Andrew J. Klink

808 total citations
61 papers, 524 citations indexed

About

Andrew J. Klink is a scholar working on Oncology, Hematology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Andrew J. Klink has authored 61 papers receiving a total of 524 indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Oncology, 14 papers in Hematology and 12 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Andrew J. Klink's work include CAR-T cell therapy research (8 papers), Chronic Lymphocytic Leukemia Research (7 papers) and Lung Cancer Treatments and Mutations (7 papers). Andrew J. Klink is often cited by papers focused on CAR-T cell therapy research (8 papers), Chronic Lymphocytic Leukemia Research (7 papers) and Lung Cancer Treatments and Mutations (7 papers). Andrew J. Klink collaborates with scholars based in United States, Germany and Switzerland. Andrew J. Klink's co-authors include Chris Feudtner, Pamela F. Weiss, Bruce A. Feinberg, Ron Keren, Ajeet Gajra, Russell Localio, Chadi Nabhan, David D. Sherry, Vinay Prasad and Xianqun Luan and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Neurology.

In The Last Decade

Andrew J. Klink

54 papers receiving 513 citations

Peers

Countries citing papers authored by Andrew J. Klink

Since Specialization

Citations

This map shows the geographic impact of Andrew J. Klink's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andrew J. Klink with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andrew J. Klink more than expected).

Fields of papers citing papers by Andrew J. Klink

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andrew J. Klink. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andrew J. Klink. The network helps show where Andrew J. Klink may publish in the future.

Co-authorship network of co-authors of Andrew J. Klink

This figure shows the co-authorship network connecting the top 25 collaborators of Andrew J. Klink. A scholar is included among the top collaborators of Andrew J. Klink based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andrew J. Klink. Andrew J. Klink is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Availability and completeness of real-world data in United States community oncology/hematology practices regarding chimeric antigen receptor (CAR T)-cell therapy for relapsed/refractory diffuse large B-cell lymphoma 2025 ·David Porter, Andrew J. Klink, (unknown), Tammy A. Schuler, Bindu Kalesan, (unknown), (unknown), (unknown), Sarah Lucht, (unknown), Bruce A. Feinberg	0
2	Real-World Patient Characteristics and Outcomes in Patients with Relapsed or Refractory Multiple Myeloma Receiving Teclistamab across Community Oncology Practices in the US 2024 ·Blood ·Binod Dhakal, Nina Kim, William S. John, Bingcao Wu, Sarah Lucht, Dee Lin, (unknown), (unknown), Bryce Van Doren, Laura Hester, (unknown), (unknown), (unknown), (unknown), Andrew J. Klink, (unknown), Bruce A. Feinberg, (unknown), (unknown), Peter M. Voorhees	1
3	Real-world outcomes associated with afatinib use in patients with solid tumors harboring NRG1 gene fusions 2024 ·Lung Cancer ·Stephen V. Liu, (unknown), (unknown), (unknown), Andrew J. Klink, Ajeet Gajra, Kristin M. Zimmerman Savill, Sushma Jonna	12
4	Real-world clinical outcomes and rationale for initiating abatacept as a first-line biologic for patients with anticitrullinated protein antibody- and rheumatoid factor-positive rheumatoid arthritis 2024 ·Journal of Comparative Effectiveness Research ·(unknown), (unknown), Andrew J. Klink, (unknown), (unknown), (unknown), (unknown), Bruce A. Feinberg, (unknown), Vadim Khaychuk, (unknown), (unknown), Gordon K. Lam	2
5	United States clinical practice experience with eculizumab in myasthenia gravis: symptoms, function, and immunosuppressant therapy use 2024 ·Journal of Neurology ·Ali A. Habib, Andrew J. Klink, Srikanth Muppidi, Anju Parthan, (unknown), (unknown), Ajeet Gajra, Richard J. Nowak, James F. Howard, (unknown)	6
6	US Clinical Practice Experience with Eculizumab in Myasthenia Gravis: Acute Clinical Events and Healthcare Resource Utilization 2024 ·Drugs - Real World Outcomes ·Richard J. Nowak, Ali A. Habib, Andrew J. Klink, Srikanth Muppidi, Anju Parthan, (unknown), (unknown), Ajeet Gajra, James F. Howard, (unknown)	1
7	1992P Real-world (RW) characteristics and outcomes in patients (pts) with muscle-invasive urothelial carcinoma (MIUC) treated with adjuvant nivolumab (NIVO) with or without neoadjuvant chemotherapy (NAC) 2024 ·Annals of Oncology ·Hooman Ebrahimi, Regina Barragán-Carrillo, Winsome St John, Sarah Lucht, Talia Miller, (unknown), (unknown), Stuart C. Gordon, (unknown), Andrew J. Klink, (unknown), (unknown), (unknown), Minesh Patel, Lisa Rosenblatt, Xiaoyan Yin, Alex Chehrazi‐Raffle	0
8	MSR101 A Novel Methodology for Assessing Response to Lymphoma Treatment in Real-World Studies – the Real-World Lugano (RWLUGANO) Study 2024 ·Value in Health ·Raghunandan Swain, (unknown), Andrew J. Klink, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Bindu Kalesan, (unknown), Neil Richardson, Marc R. Theoret, Catherine C. Lerro, Fatima Rizvi, Jonathon Vallejo, K. Wang, Diego Rivera, (unknown)	0
9	Oncologist Perceptions of Racial Disparity, Racial Anxiety, and Unconscious Bias in Clinical Interactions, Treatment, and Outcomes 2024 ·Journal of the National Comprehensive Cancer Network ·(unknown), (unknown), Ajeet Gajra, (unknown), Andrew J. Klink, (unknown), Bruce A. Feinberg	2
10	Real-world clinical outcomes with enasidenib in relapsed or refractory acute myeloid leukemia 2022 ·Leukemia Research ·Andrew J. Klink, Ajeet Gajra, Russell L. Knoth, (unknown), Ying Hou, Ali McBride, Ronda Copher	1
11	Comparison of Solid Tumor Treatment Response Observed in Clinical Practice With Response Reported in Clinical Trials 2021 ·JAMA Network Open ·Bruce A. Feinberg, Marjorie E. Zettler, Andrew J. Klink, (unknown), Ajeet Gajra, Jonathan Kish	19
12	1956P A real-world feasibility study of patients with solid tumours harbouring NRG1 gene fusions 2020 ·Annals of Oncology ·Ajeet Gajra, Andrew J. Klink, (unknown), (unknown), A. Cseh, (unknown), (unknown), (unknown)	2
13	Real-world adverse events associated with CAR T-cell therapy among adults age ≥ 65 years 2020 ·Journal of Geriatric Oncology ·Marjorie E. Zettler, Bruce A. Feinberg, (unknown), Andrew J. Klink, (unknown), Ajeet Gajra	24
14	PCN493 PERCEPTIONS OF AND PARTICIPATION IN REAL-WORLD EVIDENCE RESEARCH AMONG US COMMUNITY ONCOLOGISTS 2019 ·Value in Health ·Andrew J. Klink, Bela Bapat, Alex Russell, (unknown), (unknown)	1
15	Real-World Utilization of Midostaurin Among Patients with Systemic Mastocytosis (SM) 2019 ·Blood ·Ajeet Gajra, Andrew J. Klink, (unknown), Bruce A. Feinberg	2
16	Use Of Real-World Evidence In Clinical Decision Making By Community Oncologists 2018 ·Value in Health ·Jonathan Kish, Bruce A. Feinberg, (unknown), (unknown), (unknown), Andrew J. Klink, Chadi Nabhan	2
17	Histological features of ileitis differentiating pediatric Crohn disease from ulcerative colitis with backwash ileitis 2017 ·Digestive and Liver Disease ·Benjamin Sahn, (unknown), Ronen Stein, Eduardo D. Ruchelli, (unknown), Andrew J. Klink, Robert N. Baldassano, David A. Piccoli, Pierre Russo, Petar Mamula	10
18	The pediatric rheumatology quality of life scale: validation of the English version in a US cohort of juvenile idiopathic arthritis 2013 ·Pediatric Rheumatology ·Pamela F. Weiss, Andrew J. Klink, Jennifer Faerber, Chris Feudtner	10
19	Enthesitis in an inception cohort of enthesitis‐related arthritis 2011 ·Arthritis Care & Research ·Pamela F. Weiss, Andrew J. Klink, Edward M. Behrens, David D. Sherry, Terri H. Finkel, Chris Feudtner, Ron Keren	51
20	Temporal Association of Streptococcus, Staphylococcus, and Parainfluenza Pediatric Hospitalizations and Hospitalized Cases of Henoch-Schönlein Purpura 2010 ·The Journal of Rheumatology ·Pamela F. Weiss, Andrew J. Klink, Xianqun Luan, Chris Feudtner	43

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact